Frank Kalkbrenner

Frank is the Global Head of the Boehringer Ingelheim Venture Fund. He served as board member of STAT Diagnostica (acquired by Qiagen in 2018), Hookipa Biotech (IPO at NASDAQ in 2019) and Amal Therapeutics (acquired by Boehringer Ingelheim in 2019). Currently, he is on the Boards of Rinri Therapeutics, T3 Pharma, eTheRNA, Aelin Therapeutics, Acousia Therapeutics, and Brainomix. A physician by training, with a Ph.D. in Pharmacology and a Pharmacology and Toxicology specialist. He spent more than 10 years in academic research in the Max-Planck-Institute for Molecular Genetics and in the Institute of Pharmacology of the Freie Universität in Berlin. He began his industrial career at Schering AG and moved in 1999 to Boehringer Ingelheim joining Pulmonary Research. In 2005, he took over the responsibility for the Licensing Department. In this function, he was responsible for the licensing activities of the German Boehringer Ingelheim organization in various indication areas. He also built up the Biological Research unit at the German Research site in Biberach. Shortly after its initiation in 2010, Frank joined the Boehringer Ingelheim Venture Fund.